Tuberculosis
Short-course chemotherapy safe/effective in pediatric respiratory tuberculosis
Published in Medical Letter on the CDC and FDA, August 28th, 2005
According to a study from India, "This report presents the 5-year follow-up of 137 children with respiratory tuberculosis enrolled in a randomized clinical trial of two different antituberculosis regimens 9HR and 2HRZ(3)/4RH(2). Both regimens had similar cure rates, with low relapse rates and mortality."
"Of 134 children followed up to 5 years, 86% had normal radiographs, with more sequelae in the 9HR group (15 vs. 1.5%, p<0.01). One patient relapsed and there was one accidental death," reported S. Swaminathan and colleagues at the Indian Council for Medical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Anthrax
Complement depletion renders mice sensitive to Bacillus anthracis - Bioterrorism
Identifying microbial pathogens in post-9/11 era reviewed - Cryptosporidiosis
Unique endemicity of cryptosporidiosis in children in Kuwait described - Enterocolitis
Necrotizing enterocolitis associated with Clostridium perfringens - Metabolic Syndrome
Mortality and diabetes risks linked to metabolic syndrome reviewed - Abdominal Aortic Aneurysms
FDA approves Powerlink trials on AAA patients with large diameter aortic necks - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
